AVP-786 matching placebo
Sponsors
Otsuka Pharmaceutical Development & Commercialization Inc., Otsuka Pharmaceutical Development & Commercialization Inc., Otsuka Pharmaceutical Development & Commercialization Inc.
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Phase 3
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type
CompletedCTIS2023-504991-31-00
Start: 2021-05-06End: 2024-05-22Target: 248Updated: 2024-04-29
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type
CompletedCTIS2023-504990-19-00
Start: 2021-04-06End: 2024-05-22Target: 267Updated: 2024-05-29